



Corporate Release No 431

29 March 2011

### **A new pharmaceutical candidate enters Lundbeck's development pipeline**

H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in clinical development by initiating clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.

Lu AF11167 is a new compound inhibiting a phosphodiesterase enzyme primarily expressed in brain and here in regions relevant for a number of both neurological and psychiatric diseases in humans. By inhibiting this enzyme, Lu AF11167 boosts signalling and thus increases the activity of certain neurons in the brain.

Extensive research in animals suggests that these type of compounds have potential in e.g. Alzheimer's disease, Huntington's chorea and schizophrenia.

*"Our Focus at Lundbeck Research is to discover innovative compounds that address unmet needs in patients with CNS diseases. Lu AF11167 is an example of a new generation of compounds with a great potential for treatment of certain CNS conditions currently inadequately treated,"* says Executive Vice President Peter Høngaard Andersen, Head of Research at Lundbeck.

### **Financial guidance**

The content of this release will have no influence on the Lundbeck Group's financial guidance for 2011 which was provided on 24 February 2011 in connection with the release of the financial results for 2010.

### **Lundbeck contacts**

*Investors:*

Palle Holm Olesen  
Chief Specialist, Investor Relations  
+45 36 43 24 26

Magnus Thorstholm Jensen  
Investor Relations Officer  
+45 36 43 38 16

Jacob Tolstrup  
Vice President  
+1 847 282 5713

*Media:*

Mads Kronborg  
Media Relations Manager  
+45 36 43 28 51

Stine Hove Marsling  
External Communication Specialist  
+45 36 43 28 33

**About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit [www.lundbeck.com](http://www.lundbeck.com).